JOHNSON & JOHNSON is 368.5x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($573.98 B vs $1.56 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SNDX | JNJ |
|---|---|---|
| Market cap | $1.56 B | $573.98 B |
| US-listed rank | #2292 | #20 |
| Revenue (latest FY) | $172.35M | $94.19B |
| Net income (latest FY) | -$285.40M | $26.80B |
| Net margin | -165.6% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 636 | 984 |
JOHNSON & JOHNSON is 368.5x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($573.98 B vs $1.56 B).
In their latest fiscal years, Syndax Pharmaceuticals Inc reported $172.35M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Syndax Pharmaceuticals Inc and JOHNSON & JOHNSON, or browse the full rankings.